Senseonics (NYSE:SENS) Director Buys $65,500.00 in Stock

Senseonics Holdings, Inc. (NYSE:SENS) Director Edelman Steven bought 10,000 shares of Senseonics stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average cost of $6.55 per share, for a total transaction of $65,500.00. Following the purchase, the director owned 74,708 shares of the company’s stock, valued at $489,337.40. The trade was a 15.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Senseonics Price Performance

SENS opened at $6.26 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The stock has a market capitalization of $255.77 million, a P/E ratio of -48.15 and a beta of 0.79. The stock has a 50-day moving average price of $8.16 and a 200-day moving average price of $9.64. Senseonics Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $28.00.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SENS shares. Stifel Nicolaus started coverage on Senseonics in a research note on Tuesday, October 21st. They set a “hold” rating and a $9.00 price objective on the stock. HC Wainwright raised their price target on Senseonics to $18.50 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Barclays reaffirmed an “overweight” rating and issued a $31.00 price target (up from $1.50) on shares of Senseonics in a research note on Wednesday, November 5th. Finally, TD Cowen dropped their price objective on Senseonics from $25.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $22.70.

Institutional Investors Weigh In On Senseonics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC lifted its position in Senseonics by 666.7% during the second quarter. First Light Asset Management LLC now owns 35,708,124 shares of the company’s stock valued at $17,011,000 after acquiring an additional 31,050,619 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Senseonics by 2.2% in the third quarter. Vanguard Group Inc. now owns 34,219,484 shares of the company’s stock worth $14,920,000 after buying an additional 749,453 shares during the last quarter. Geode Capital Management LLC lifted its position in Senseonics by 26.6% during the 2nd quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company’s stock worth $4,147,000 after acquiring an additional 1,828,302 shares during the period. Hood River Capital Management LLC purchased a new stake in Senseonics in the second quarter valued at approximately $3,775,000. Finally, Masters Capital Management LLC increased its stake in shares of Senseonics by 11.1% in the third quarter. Masters Capital Management LLC now owns 5,000,000 shares of the company’s stock worth $2,179,000 after acquiring an additional 500,000 shares during the period. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.